Significant progress in HER2 mutated non-small cell lung cancer with PB272, as well as HER2-negative breast cancer patients with the HER2 mutation, adds significant weight to the report earlier last month ( Dec 4 ) of top line results from the Phase 2 neoadjuvant treatment work done in breast cancer (I-SPY 2 TRIAL). I-SPY 2 essentially looked at Stage 2 (HER2-positive breast cancer) and higher women, to see how effective Neratinib could be in combination with standard chemotherapy in a neoadjuvant context and having graduated this unique trial, which is a collaborative effort from 20 major cancer research centers across the U.S. (as well as the FDA and major industry and foundation supporters), with statistically superior performance (Paclitaxel plus Neratinib versus Paclitaxel plus Trastuzuma), PBYI has been really starting to turn heads in the oncology space for their technology.